Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; Department of Internal Medicine, Hallym Hospital, Incheon, Republic of Korea.
J Crit Care. 2017 Oct;41:36-41. doi: 10.1016/j.jcrc.2017.04.045. Epub 2017 Apr 30.
Diuretics are used frequently in critically ill patients. We investigated the effects of furosemide on the prognosis.
Following a retrospective review of patients admitted to the medical intensive care unit (ICU), we analyzed risk factors with variables including initial furosemide dose for ICU mortality.
A total of 448 patients were included. Total furosemide dose during the first three days of the ICU stay (odds ratio (OR) 2.35, 95% confidence interval (CI) 1.01-5.02) and fluid balance during the same period (OR 3.04, 95% CI 1.46-6.31) were associated with ICU mortality, as were malignancy, chronic furosemide use, and APACHE II score. However, in oliguric patients, positive fluid balance was associated with ICU mortality (OR 22.33, 95% CI 1.82-273.72) but the high-dose furosemide was not. In contrast, in non-oliguric patients, high-dose furosemide was associated with ICU mortality (OR 2.47, 95% CI 1.01-5.68); however, the positive fluid balance showed only a trend for high ICU mortality.
Early high-dose furosemide use is associated with ICU mortality, particularly in non-oliguric patients. We suggest that furosemide should be used with caution even in non-oliguric critically ill patients until the safety is confirmed in powered study.
利尿剂在危重症患者中经常使用。我们研究了呋塞米对预后的影响。
我们对入住内科重症监护病房(ICU)的患者进行回顾性分析,分析了包括 ICU 死亡率初始呋塞米剂量在内的变量的危险因素。
共纳入 448 例患者。ICU 入住前 3 天的总呋塞米剂量(比值比(OR)2.35,95%置信区间(CI)1.01-5.02)和同期的液体平衡(OR 3.04,95%CI 1.46-6.31)与 ICU 死亡率相关,恶性肿瘤、慢性呋塞米使用和 APACHE II 评分也是如此。然而,在少尿患者中,正性液体平衡与 ICU 死亡率相关(OR 22.33,95%CI 1.82-273.72),但高剂量呋塞米则不然。相反,在非少尿患者中,高剂量呋塞米与 ICU 死亡率相关(OR 2.47,95%CI 1.01-5.68);然而,正性液体平衡仅显示出 ICU 死亡率较高的趋势。
早期大剂量呋塞米的使用与 ICU 死亡率相关,特别是在非少尿的危重症患者中。我们建议,在非少尿的危重症患者中,即使在安全得到证实的研究中,也应谨慎使用呋塞米。